NIH, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) NIH - National Institutes of Health National Cancer Institute DCTD - Division of Cancer Treatment and Diagnosis
Advanced SearchBrowse by AnalyteBrowse by Pre-analytical FactorSearch SOPsSOP Compendiums

Effects of anticoagulants on the activity of gelatinases.

Author(s): Castellazzi M, Tamborino C, Fainardi E, Manfrinato MC, Granieri E, Dallocchio F, Bellini T

Publication: Clin Biochem, 2007, Vol. 40, Page 1272-6

PubMed ID: 17904541 PubMed Review Paper? No

Purpose of Paper

The purpose of this paper was to determine the effects of anticoagulants on the activity of matrix metalloproteinase (MMP)-2 and 9 in plasma and serum.

Conclusion of Paper

The average concentrations of MMP-2 and MMP-9 were highest in EDTA-plasma followed by serum and citrated plasma, which had similar levels to each other. Heparinated plasma had the lowest levels of MMP-2 and MMP-9. Treatment of pooled serum with EDTA resulted in significantly increased active MMP-2 and MMP-9 levels, while treatment of pooled serum with heparin resulted in significantly decreased activity for both enzymes. Treatment of pooled serum with citrate resulted in much smaller changes in levels of active MMP-2 and MMP-9.

Studies

  1. Study Purpose

    The purpose of this study was to determine the effects of anticoagulants on the activity of MMP-2 and MMP-9 in plasma and serum from healthy volunteers. In addition to assaying individual and pooled serum specimens collected in plain tubes, pooled serum specimens that had been transferred to the blood collection tubes containing anticoagulants were assayed. Serum and plasma were aliquoted and stored at -70 degrees C until assay.

    Summary of Findings:

    The average concentrations of MMP-2 and MMP-9 were significantly higher in K2EDTA-plasma than in serum (p<0.0001, and p<0.01, respectively), heparinated plasma (both p<0.0001), or citrated plasma (p<0.0001, and p<0.01, respectively). Heparinated plasma had lower average levels of MMP-2 and MMP-9 than serum (p<0.0001 and p<0.05, respectively), or citrated plasma (p<0.0001 and p<0.01, respectively), which did not have significantly different average MMP-2 or MMP-9 levels from one another. Treatment of pooled serum with K2EDTA resulted in significantly increased active MMP-2 (+640.2%) and MMP-9 levels (+150.6%), while treatment of pooled serum with heparin resulted in significantly decreased activity for both enzymes (-51.4% and -62.6%, respectively) compared to untreated pooled serum. Treatment of pooled serum with citrate resulted in much smaller changes in levels of active MMP-2 (-14.0%) and MMP-9 (+10.4%).

    Biospecimens
    Preservative Types
    • Frozen
    Diagnoses:
    • Normal
    Platform:
    AnalyteTechnology Platform
    Protein Enzyme assay
    Pre-analytical Factors:
    ClassificationPre-analytical FactorValue(s)
    Biospecimen Aliquots and Components Blood and blood products Plasma
    Serum
    Biospecimen Acquisition Anticoagulant None
    Lithium heparin
    Potassium EDTA
    Sodium citrate
    View more

You Recently Viewed  

News and Announcements

  • Most Downloaded SOPs in 2024
  • New Articles on the GTEx Project are Now FREELY Available!
  • Just Published!
    • More...